Lexicon Pharmaceuticals (LXRX) Cash from Investing Activities: 2009-2024
Historic Cash from Investing Activities for Lexicon Pharmaceuticals (LXRX) over the last 16 years, with Dec 2024 value amounting to -$15.4 million.
- Lexicon Pharmaceuticals' Cash from Investing Activities fell 137.32% to -$6.7 million in Q4 2012 from the same period last year, while for Dec 2012 it was -$97.8 million, marking a year-over-year decrease of 239.81%. This contributed to the annual value of -$15.4 million for FY2024, which is 69.21% up from last year.
- Latest data reveals that Lexicon Pharmaceuticals reported Cash from Investing Activities of -$15.4 million as of FY2024, which was up 69.21% from -$49.9 million recorded in FY2023.
- In the past 5 years, Lexicon Pharmaceuticals' Cash from Investing Activities registered a high of $380.8 million during FY2020, and its lowest value of -$71.1 million during FY2022.
- Moreover, its 3-year median value for Cash from Investing Activities was -$49.9 million (2023), whereas its average is -$45.5 million.
- Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 344.30% in 2020, then plummeted by 3,468.63% in 2022.
- Lexicon Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $380.8 million in 2020, then tumbled by 99.45% to $2.1 million in 2021, then slumped by 3,468.63% to -$71.1 million in 2022, then climbed by 29.73% to -$49.9 million in 2023, then soared by 69.21% to -$15.4 million in 2024.